Friday, 16 October 2026European Markets

LNA SANTE And MEDISTIM Have A High Dividend Yield And Return On Equity In The Healthcare Sector.

Loading stream...

(vianews) - lna sante (lna.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.

financial asset price forward dividend yield return on equity
lna sante (lna.pa) €19.40 2.54% 9.08%
medistim (medi.ol) kr181.00 2.36% 27.12%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. lna sante (lna.pa)

2.54% forward dividend yield and 9.08% return on equity

lna santé sa engages in the management and operation of health establishments. the company operates retirement homes, medical and rehabilitation care, home hospital, surgery, mental health clinic, and health center. lna santé sa was founded in 1990 and is based in vertou, france.

earnings per share

as for profitability, lna sante has a trailing twelve months eps of €2.28.

pe ratio

lna sante has a trailing twelve months price to earnings ratio of 8.51. meaning, the purchaser of the share is investing €8.51 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.08%.

volatility

lna sante's last week, last month's, and last quarter's current intraday variation average was a negative 3.22%, a negative 0.32%, and a positive 1.68%.

lna sante's highest amplitude of average volatility was 3.22% (last week), 1.61% (last month), and 1.68% (last quarter).

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, lna sante's stock is considered to be overbought (>=80).

more news about lna sante.

2. medistim (medi.ol)

2.36% forward dividend yield and 27.12% return on equity

medistim asa develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the united states, europe, asia, and internationally. it offers miraq cardiac, a system that combines ultrasound imaging and transit time flow measurement (ttfm) in a single system for cardiac surgery; miraq vascular, a system that combines ultrasound imaging and transit ttfm in a single system for vascular surgery; and imaging probes for intraoperative use. the company also provides various flow probes, such as quickfit ttfm probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; vascular ttfm probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. in addition, it distributes and sells third party medical equipment. the company was incorporated in 1984 and is headquartered in oslo, norway.

earnings per share

as for profitability, medistim has a trailing twelve months eps of kr5.68.

pe ratio

medistim has a trailing twelve months price to earnings ratio of 31.87. meaning, the purchaser of the share is investing kr31.87 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 27.12%.

earnings before interest, taxes, depreciation, and amortization

medistim's ebitda is 97.92.

revenue growth

year-on-year quarterly revenue growth declined by 0.4%, now sitting on 526.36m for the twelve trailing months.

moving average

medistim's worth is way under its 50-day moving average of kr207.18 and way under its 200-day moving average of kr222.82.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on apr 25, 2023, the estimated forward annual dividend rate is 4.5 and the estimated forward annual dividend yield is 2.36%.

more news about medistim.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com